Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—A meta-analysis
Abstract
Objective: To describe the relative risk for venous thrombosis (VT) associated with antiphos pholipid antibodies (aPL) in systemic lupus erythematosus (SLE). Design: Systematic review and meta-analysis of 26 articles that examined the association between aPL and VT in SLE. Setting: Mostly secondary and tertiary referral centres. Patients: 2249 patients with SLE, 1120 tested for LA (lupus anticoagulant) and 1563 tested for aCL (anticardiolipin antibodies). Main outcome measures: A summary of study characteristics and a critical appraisal of study quality were done. Two statistical combinations of 18 primary studies that examined the association of VT and LA and of 14 studies that examined the association of VT and aCL were performed to estimate the risk for VT associated with aPL. Results: The odds ratios of the risk of VT related to the LA summarized from 18 studies were 5.61 [95% CI; 3.80-8.27] overall, 6.32 [CI; 3.71-10.78] for deep venous thrombosis and pulmonary embolism, 11.6 [3.65--36.91] for recurrent venous thrombosis after the first event. The odds ratios of the risk of VT related to aCL summarized from 14 studies were 2.17 [95% CI; 1.51-3.11] overall, 2.50 [CI; 1.51-4.14] for deep venous thrombosis and pulmonary embolism, 3.91 [1.14- 13.38] for recurrent venous thrombosis after the first event. Conclusions: Patients with SLE and LA are at approximately six times greater risk for VT than patients without LA, whereas patients with SLE and aCL are approximately two times greater risk for VT than patients without aCL. We have identified important methodologic limitations and differences in study characteristics. Other risk factors for VT have not been thoroughly evaluated in these studies. Further studies are needed that provide an accurate estimate of the absolute risk for aPL related VT.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Cites
Statistical Methods in Medical Research.
Armitage, P. (1972) · Biometrics · doi:10.2307/2556182 · Cited by 5,383 · see citing works
Alarcón-Segovia, D., Delezé, M., Oria, C. V., Sánchez‐Guerrero, J., Gómez-Pacheco, L., Cabiedes, J., Fernández, L. A. N., & de León, S. P. (1989) · Medicine · doi:10.1097/00005792-198911000-00003 · Cited by 635 · see citing works
Clinical Recommendations Using Levels of Evidence for Antithrombotic Agents
Cook, D. J., Guyatt, G. H., Laupacis, A., Sackett, D. L., & Goldberg, R. J. (1995) · CHEST Journal · doi:10.1378/chest.108.4_supplement.227s · Cited by 275 · see citing works
Horbach, D. A., van Oort, E., Donders, R. C. J. M., Derksen, R. H. W. M., & de Groot, P. G. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650686 · Cited by 246 · see citing works
Anglés‐Cano, E., Sultan, Y., & Clauvel, J. (1979) · PubMed · Cited by 219 · see citing works
Thrombosis in Systemic Lupus Erythematosus
Glueck, H. I. (1985) · Archives of Internal Medicine · doi:10.1001/archinte.1985.00360080059007 · Cited by 192 · see citing works
KALUNIAN, K. C., Middlekauff, H. R., Sayre, J. A., Ando, D. G., Mangotich, M., Hahn, B. H., & Peter, J. B. (1988) · The American Journal of Medicine · doi:10.1016/s0002-9343(88)80229-8 · Cited by 150 · see citing works
Anticardiolipin antibodies in patients with systemic lupus erythematosus
Sturfelt, G. K., Nived, O., Norberg, R., Thorstensson, R., & Krook, K. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780300404 · Cited by 124 · see citing works
Worrall, J. G., SNAITH, M. L., Batchelor, J. R., et al. (1990) · QJM · doi:10.1093/oxfordjournals.qjmed.a068440 · Cited by 114 · see citing works
Platelet Function and Coagulation Profile in Lupus Erythematosus
Regan, M. G., LACKNER, H., & KARPATKIN, S. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-4-462 · Cited by 109 · see citing works
Anticardiolipin antibodies in unselected autoimmune rheumatic disease patients
Manoussakis, M. N., Gharavi, A. E., Drosos, A. A., Kitridou, R. C., & Moutsopoulos, H. Μ. (1987) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(87)90073-0 · Cited by 103 · see citing works
Ginsberg, J. S., Demers, C., Brill-Edwards, P. A., et al. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80317-9 · Cited by 77 · see citing works
McHugh, N. J., Maymó, J., Skinner, R. P., et al. (1988) · Annals of the Rheumatic Diseases · doi:10.1136/ard.47.2.110 · Cited by 74 · see citing works
A Survey of Current Problems in Meta-Analysis
Hasselblad, V., Mosteller, F. C., Littenberg, B., Chalmers, T. C., Hunink, M. G. M., Turner, J. A., Morton, S. C., Diehr, P. H., Wong, J. B., & Powe, N. R. (1995) · Medical Care · doi:10.1097/00005650-199533020-00007 · Cited by 61 · see citing works
Renal vein thrombosis and inferior vena cava thrombosis in systemic lupus erythematosus
Mintz, G., Acevedo‐Vásquez, E. M., Gutiérrez‐Espinosa, G., et al. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270509 · Cited by 55 · see citing works
Ghirardello, A., Doria, A., Ruffatti, A., Rigoli, A. M., Vesco, P., Calligaro, A., & Gambari, P. F. (1994) · Annals of the Rheumatic Diseases · doi:10.1136/ard.53.2.140 · Cited by 48 · see citing works
LUPUS ANTICOAGULANT AS A PROGNOSTIC MARKER IN SYSTEMIC LUPUS ERYTHEMATOSUS
Jouhikainen, T., Stephansson, E., & Leirisalo‐Repo, M. (1993) · Lara D. Veeken · doi:10.1093/rheumatology/32.7.568 · Cited by 42 · see citing works
Haemostatic Abnormalities in Systemic Lupus Erythematosus
Gladman, D. D., UROWITS, M. B., Tozman, E. C., et al. (1983) · QJM · doi:10.1093/oxfordjournals.qjmed.a067771 · Cited by 38 · see citing works
Gharavi, A. E., & Wilson, W. (1996) · Lupus · doi:10.1177/096120339600500501 · Cited by 37 · see citing works
Circulating Anticoagulant in Systemic Lupus erythematosus: Clinical Manifestations
Pauzner, R., Rosner, E., & Many, A. (2009) · Acta Haematologica · doi:10.1159/000206028 · Cited by 34 · see citing works
The Prevalence and Clinical Associations of the Lupus Anticoagulant in Systemic Lupus Erythematosus
Derksen, R. H. W. M., Bouma, B. N., & Kater, L. (1987) · Scandinavian Journal of Rheumatology · doi:10.3109/03009748709165272 · Cited by 32 · see citing works
Anticardiolipin antibodies in patients from Malaysia with systemic lupus erythematosus.
Jones, H. W., Ireland, R. M., Senaldi, G., et al. (1991) · Annals of the Rheumatic Diseases · doi:10.1136/ard.50.3.173 · Cited by 31 · see citing works
Wong, K.-L., Liu, H., Ho, K., et al. (1991) · PubMed · Cited by 31 · see citing works
Lupus Anticoagulant, Thrombosis and Thrombocytopenia in Systemic Lupus Erythematosus
Averbuch, M., Koifman, B., & Levo, Y. (1987) · The American Journal of the Medical Sciences · doi:10.1097/00000441-198701000-00002 · Cited by 28 · see citing works
Jouhikainen, T., Kekomäki, R., Leirisalo‐Repo, M., Bäcklund, T., & Myllylä, G. (1990) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1990.tb00385.x · Cited by 25 · see citing works
McHugh, N. J., Moye, D. A., James, I. E., Sampson, M., & Maddison, P. J. (1991) · Annals of the Rheumatic Diseases · doi:10.1136/ard.50.8.548 · Cited by 21 · see citing works
Treatment of carrageenan induced arthritis by the platelet activating factor antagonist BN 50730.
Hilliquin, P., Natour, J., Aïssa, J., et al. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.2.140 · Cited by 11 · see citing works
Metz, D., Jolly, D., Graciet-Richard, J., et al. (1994) · PubMed · Cited by 7 · see citing works
Ferro, D., Saliola, M., Quintarelli, C., et al. (1990) · Thrombosis Research · doi:10.1016/0049-3848(90)90419-d · Cited by 5 · see citing works
Flagged first, then by citations
Research works printed but not linked: 9
- Chalmers I, 1995, Systematic Reviews
- Bowie Ejw, 1963, Clin Med, 62, 416
- Angles-Cano E., 1979, J Lab Clin Med, 94, 312
- Gladman DD, 1983, Q J Med, 52, 424
- Petri M., 1987, Arch Intern Med, 106, 524
- Rowell NR, 1989, Acta Derm Venereol (Stockh), 69, 111
- Worrall JG, 1990, Q J Med, 74, 319
- Wong KL, 1991, J Rheumatol, 18, 1187
- Metz D., 1994, Presse Med, 23, 1797
Cited by
Sorted by citations
Levine, J. S., Branch, D. W., & Rauch, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmra002974 · Cited by 1,524 · see citing works
“It was also shown (17, 18, 19, 20) that discontinuation of anticoagulants seems to be associated with an increased risk of thrombosis (up to 70 %), and even death, especially in the first six months : anticoagulation should therefore be long term, if not lifelong.”
BackgroundU.S. Medical Eligibility Criteria for Contraceptive Use, 2016
Curtis, K. M., Tepper, N. K., Jatlaoui, T. C., Berry-Bibee, E., Horton, L. G., Zapata, L. B., Simmons, K. B., Pagano, H. P., Jamieson, D. J., & Whiteman, M. K. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6503a1 · Cited by 1,456 · see citing works
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 974 · see citing works
Combes, V., Simon, A.-C., Grau, G. E., Arnoux, D., Camoin‐Jau, L., Sabatier, F., Mutin, M., Sanmarco, M., Sampol, J., & Dignat‐George, F. (1999) · Journal of Clinical Investigation · doi:10.1172/jci4985 · Cited by 731 · see citing works
“This coagulation abnormality is well recognized to be strongly associated with a thrombotic tendency (31, 32).”
BackgroundThe Pathogenesis of the Antiphospholipid Syndrome
Giannakopoulos, B., & Krilis, S. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1112830 · Cited by 682 · see citing works
Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19
Zuo, Y., Estes, S. K., Ali, R. A., Gandhi, A. A., Yalavarthi, S., Shi, H., Sule, G. J., Gockman, K., Madison, J. A., Zuo, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3876 · Cited by 658 · see citing works
Epidemiology of the Antiphospholipid Antibody Syndrome
Petri, M. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.2000.0409 · Cited by 468 · see citing works
Tektonidou, M. G., Laskari, K., Panagiotakos, D. B., & Moutsopoulos, H. M. (2009) · Arthritis Care & Research · doi:10.1002/art.24232 · Cited by 356 · see citing works
Antibody profiles for the diagnosis of antiphospholipid syndrome
Biasiolo, A., Pegoraro, C., Cucchini, U., Noventa, F., Iliceto, S., & Pengo, V. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-12-0839 · Cited by 318 · see citing works
U.S. Medical Eligibility Criteria for Contraceptive Use, 2010
Curtis, K. M., Tepper, N. K., & Marchbanks, P. A. (2011) · Journal of Women s Health · doi:10.1089/jwh.2011.2851 · Cited by 262 · see citing works
Sciascia, S., Sanna, G., Murru, V., Roccatello, D., Khamashta, M. A., & Bertolaccini, M. L. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-06-0509 · Cited by 253 · see citing works
PREMATURE ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS
Bruce, I. N., Gladman, D. D., & Urowitz, M. B. (2000) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70138-1 · Cited by 241 · see citing works
U.S. Medical Eligibility Criteria for Contraceptive Use, 2024
Nguyen, A. T., Curtis, K. M., Tepper, N. K., Kortsmit, K., Brittain, A. W., Snyder, E. M., Cohen, M. A., Zapata, L. B., Whiteman, M. K., Contributors, et al. (2024) · MMWR Recommendations and Reports · doi:10.15585/mmwr.rr7304a1 · Cited by 286 · see citing works
Arnaud, L., Mathian, A., Ruffatti, A., Erkan, D., Tektonidou, M., Cervera, R., Forastiero, R., Pengo, V., Lambert, M., Martinez-Zamora, M. A., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.10.014 · Cited by 215 · see citing works
Self-citationThe clinical significance of antiphospholipid antibodies in systemic lupus erythematosus
Ünlü, O., Zuily, S., & Erkan, D. (2015) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2015.0085 · Cited by 210 · see citing works
Lupus anticoagulants and the risk of a first episode of deep venous thrombosis
DE GROOT, P. G., LUTTERS, B., DERKSEN, R. H. W. M., LISMAN, T., MEIJERS, J. C. M., & ROSENDAAL, F. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01485.x · Cited by 205 · see citing works
Hanly, J. G., Urowitz, M. B., Siannis, F., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23218 · Cited by 198 · see citing works
DANOWSKI, A., de AZEVEDO, M. N. L., de SOUZA PAPI, J. A., & PETRI, M. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081194 · Cited by 192 · see citing works
How we diagnose the antiphospholipid syndrome
Giannakopoulos, B., Passam, F. H., Ioannou, Y., & Krilis, S. A. (2008) · Blood · doi:10.1182/blood-2007-12-129627 · Cited by 186 · see citing works
The geoepidemiology of the antiphospholipid antibody syndrome
Biggioggero, M., & Meroni, P. L. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.11.013 · Cited by 185 · see citing works
“A meta-analysis on the association between aPL and VTE in SLE found that LAC positive patients have a six fold greater risk for VTE than negative patients, whereas aCL positive patients have a twofold greater risk for VTE than the negative ones [26].”
BackgroundWahl, D. G., Guillemin, F., de Maistre, E., Perret‐Guillaume, C., Lecompte, T., & Thibaut, G. (1998) · Lupus · doi:10.1191/096120398678919688 · Cited by 184 · see citing works
Self-citationOxidative modification of low-density lipoprotein and immune regulation of atherosclerosis
Matsuura, E., Kobayashi, K., TABUCHI, M., & LOPEZ, L. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.05.001 · Cited by 183 · see citing works
Zuily, S., Regnault, V., Selton‐Suty, C., Eschwège, V., Bruntz, J. F., Bode-Dotto, E., de Maistre, E., Dotto, P., Perret‐Guillaume, C., Lecompte, T., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.028522 · Cited by 177 · see citing works
Self-citationJankowski, M., Vreys, I., Wittevrongel, C., Boon, D., Vermylen, J., Hoylaerts, M., & Arnout, J. (2002) · Blood · doi:10.1182/blood-2002-05-1310 · Cited by 175 · see citing works
“The thrombogenic effect of the aCL-positive but LA-negative anti-β2GPI Mab 11E8 was not significant, a finding that is in line with the clinical observation that a LA is more strongly associated with thrombosis than aCL (20, 21).”
BackgroundResultWahl, D. G., Bounameaux, H., de Moerloose, P., & Sarasin, F. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.13.2042 · Cited by 155 · see citing works
Self-citationJennekens, F. G. I. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.6.619 · Cited by 147 · see citing works
Antiphospholipid syndrome: an overview.
Hanly, J. G. (2003) · Europe PMC (PubMed Central) · Cited by 141 · see citing works
Alén, J. C., Toloza, S., Fernández, M., Bastian, H. M., Fessler, B. J., Roseman, J. M., McGwin, G., Vilá, L. M., Reveille, J. D., Alarcón, G. S., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21149 · Cited by 147 · see citing works
(2019) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000003072 · Cited by 147 · see citing works
Ho, K. T., Ahn, C. W., Alarcón, G. S., Baethge, B. A., Tan, F. K., Roseman, J., Bastian, H. M., Fessler, B. J., McGwin, G., Vilá, L. M., et al. (2005) · Rheumatology · doi:10.1093/rheumatology/kei014 · Cited by 128 · see citing works
“with arterial events [2, 40], which may in part explain our negative findings; in fact, in separate analyses, LAC was found to be associated with venous thrombotic events [42].”
ResultAntiphospholipid Syndrome: Diagnostic Aspects of Lupus Anticoagulants
Arnout, J. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616204 · Cited by 121 · see citing works
Laboratory Tests in the Diagnosis and Follow-Up of Pediatric Rheumatic Diseases: An Update
Breda, L., Nozzi, M., Sanctis, S. D., & Chiarelli, F. (2009) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.12.001 · Cited by 117 · see citing works
Samama, M. M., Dahl, O. E., Quinlan, D. J., et al. (2003) · PubMed · Cited by 115 · see citing works
Pulmonary and Thrombotic Manifestations of Systemic Lupus Erythematosus
Swigris, J. J., Fischer, A., Gilles, J., Meehan, R. T., & Brown, K. K. (2008) · CHEST Journal · doi:10.1378/chest.07-0079 · Cited by 113 · see citing works
Amarnani, R., Yeoh, S., Denneny, E. K., & Wincup, C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.610257 · Cited by 108 · see citing works
“In comparison, a positive anti-cardiolipin antibody carried twice the risk when compared with SLE patients without positive anti-cardiolipin antibodies (72).”
BackgroundArnout, J., & Vermylen, J. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00125.x · Cited by 107 · see citing works
Male, C., Foulon, D., Hoogendoorn, H., Vegh, P., Silverman, E., David, M., & Mitchell, L. (2005) · Blood · doi:10.1182/blood-2005-05-2048 · Cited by 106 · see citing works
“Testing for LAs was performed according to the criteria of the Subcommittee on APLA of the International Society of Thrombosis and Haemostasis24 as previously described in detail19: (1) screening assays included the kaolin clotting time, dilute activated partial thromboplastin time (aPTT), dilute prothrombin time, and…”
MethodResultA protocol for determination of anticardiolipin antibodies by ELISA
Pierangeli, S. S., & Harris, E. N. (2008) · Nature Protocols · doi:10.1038/nprot.2008.48 · Cited by 106 · see citing works
Update on anti-phospholipid antibodies in SLE: the Hopkins’ Lupus Cohort
Petri, M. (2010) · Lupus · doi:10.1177/0961203309360541 · Cited by 98 · see citing works
Petri, M. (2020) · Translational research · doi:10.1016/j.trsl.2020.04.006 · Cited by 101 · see citing works
Dyslipidaemia in Rheumatological Autoimmune Diseases
Toms, T. E., Panoulas, V. F., & Kitas, G. D. (2011) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401105010064 · Cited by 95 · see citing works
“[106] Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G.”
BackgroundPleural and pulmonary involvement in systemic lupus erythematosus
Torre, O., & Harari, S. A. (2010) · La Presse Médicale · doi:10.1016/j.lpm.2010.11.004 · Cited by 94 · see citing works
Laboratory diagnosis of the antiphospholipid syndrome
Wislöff, F., Jacobsen, E. M., & Liestøl, S. (2002) · Thrombosis Research · doi:10.1016/s0049-3848(02)00400-0 · Cited by 92 · see citing works
“In SLE (secondary APS), aCL or LA positivity defines a group with a substantially increased risk of pregnancy complications and venous and arterial thrombosis [19–21].”
BackgroundIncidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus
Shariati‐Sarabi, Z., Chang, E. R., Bobba, R. S., Ibañez, D., Gladman, D. D., Urowitz, M. B., & Fortin, P. R. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21314 · Cited by 90 · see citing works
Sevim, E., Zisa, D., Andrade, D., Sciascia, S., Pengo, V., Tektonidou, M. G., Ugarte, A., Gerosa, M., Belmont, H. M., Zamorano, M. A. A., et al. (2022) · Arthritis Care & Research · doi:10.1002/acr.24468 · Cited by 88 · see citing works
How I treat the antiphospholipid syndrome
Giannakopoulos, B., & Krilis, S. A. (2009) · Blood · doi:10.1182/blood-2009-05-220756 · Cited by 83 · see citing works
Rintelen, C., Vormittag, R., Sailer, T., Lehr, S., Quehenberger, P., Rumpold, H., Male, C., & Pabinger, I. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01394.x · Cited by 82 · see citing works
Pediatric Antiphospholipid Syndrome
Cimaz, R., & Descloux, É. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.05.005 · Cited by 81 · see citing works
Venous Thrombosis in the Antiphospholipid Syndrome
Farmer-Boatwright, M. K., & Roubey, R. A. S. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.182204 · Cited by 79 · see citing works
Which are the Best Biological Markers of the Antiphospholipid Syndrome?
Carreras, L. O., Forastiero, R. R., & Martinuzzo, M. E. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.2000.0401 · Cited by 78 · see citing works
EPIDEMIOLOGY OF VENOUS THROMBOEMBOLIC DISEASE
Kim, V., & Spandorfer, J. M. (2001) · Emergency Medicine Clinics of North America · doi:10.1016/s0733-8627(05)70221-2 · Cited by 78 · see citing works
Phenotyping the haemostatic system by thrombography—potential for the estimation of thrombotic risk
Regnault, V., Hemker, H. C., Wahl, D. G., et al. (2004) · Thrombosis Research · doi:10.1016/j.thromres.2004.06.017 · Cited by 78 · see citing works
Self-citationSimmelink, M. J. A., Derksen, R. H. W. M., Arnout, J., & de Groot, P. G. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00146.x · Cited by 77 · see citing works
Oxidized LDL/β2-glycoprotein I complexes: new aspects in atherosclerosis
Matsuura, E., Kobayashi, K., Inoue, K., Lopez, L. R., & Shoenfeld, Y. (2005) · Lupus · doi:10.1191/0961203305lu2211oa · Cited by 77 · see citing works
Male, C., Mitchell, L. G., Julian, J. A., et al. (2001) · Blood · doi:10.1182/blood.v97.4.844 · Cited by 77 · see citing works
NAESS, I. A., CHRISTIANSEN, S. C., CANNEGIETER, S. C., ROSENDAAL, F. R., & HAMMERSTROEM, J. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01691.x · Cited by 74 · see citing works
Clinical and laboratory manifestations of anti-factor V antibodies
Ortel, T. L. (1999) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(99)90062-8 · Cited by 74 · see citing works
Epidemiology of acute deep vein thrombosis
Bulger, C. M., Jacobs, C. E., & Patel, N. H. (2004) · Techniques in vascular and interventional radiology · doi:10.1053/j.tvir.2004.02.001 · Cited by 73 · see citing works
Runchey, S. S., Folsom, A. R., Tsai, M. Y., Cushman, M., & McGovern, P. D. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03949.x · Cited by 72 · see citing works
“ACA appear to increase the risk of VTE approximately twofold in the presence of autoimmune disease (Love & Santoro, 1990; Wahl et al, 1997; McCrae et al, 2001).”
BackgroundA two‐step coagulation test to identify antiβ2‐glycoprotein I lupus anticoagulants
Pengo, V., Biasiolo, A., Pegoraro, C., & Iliceto, S. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00712.x · Cited by 70 · see citing works
Stratifying management of rheumatic disease for pregnancy and breastfeeding
Giles, I., Yee, C., & Gordon, C. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0240-8 · Cited by 70 · see citing works
Safety of Contraceptive Method Use Among Women With Systemic Lupus Erythematosus
Culwell, K. R., Curtis, K. M., & Cravioto, M. D. C. (2009) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3181ae9c64 · Cited by 70 · see citing works
Chabbert‐Buffet, N., Amoura, Z., Scarabin, P., Francès, C., Lévy, D., Galicier, L., Wechsler, B., Blétry, O., Pietté, J. C., & Gompel, A. (2010) · Contraception · doi:10.1016/j.contraception.2010.08.012 · Cited by 67 · see citing works
“The incidence of DVT in SLE has been estimated to be between 13 and 63/1000 patient-years [43].”
BackgroundZuily, S., de Laat, B., Mohamed, S., Kelchtermans, H., Shums, Z., Albesa, R., Norman, G. L., Lamboux-Matthieu, C., Rat, A., Ninet, J., et al. (2015) · Rheumatology · doi:10.1093/rheumatology/kev238 · Cited by 69 · see citing works
Self-citationRespiratory involvement in systemic lupus erythematosus
Carmier, D., Marchand-Adam, S., Diot, P., & Diot, É. (2010) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2010.01.003 · Cited by 68 · see citing works
Tripodi, A., Biasiolo, A., Chantarangkul, V., & Pengo, V. (2003) · Clinical Chemistry · doi:10.1373/49.10.1608 · Cited by 65 · see citing works
Thromboembolic Disease after Total Hip Arthroplasty
Beksaç, B., Valle, A. G. D., & Salvati, E. A. (2006) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000238848.41670.41 · Cited by 62 · see citing works
Zuily, S., Domingues, V., Selton‐Suty, C., Eschwège, V., Bertoletti, L., Chaouat, A., Chabot, F., Regnault, V., Horn, E. M., Erkan, D., et al. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.04.003 · Cited by 62 · see citing works
Self-citationChock, Y. P. E., Moulinet, T., Dufrost, V., Erkan, D., Wahl, D. G., & Zuily, S. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102395 · Cited by 57 · see citing works
Self-citationThe Clinical Spectrum of Antiphospholipid Syndrome
Baker, W., & Bick, R. L. (2008) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.10.007 · Cited by 56 · see citing works
Riancho‐Zarrabeitia, L., Martínez-Taboada, V. M., Rúa‐Figueroa, Í., Sánchez‐Alonso, F., Galindo-Izquierdo, M., Ovalles-Bonilla, J. G., Olivé, A., Fernández‐Nebro, A., Alén, J. C., Menor-Almagro, R., et al. (2020) · Lupus · doi:10.1177/0961203320950477 · Cited by 55 · see citing works
Pediatric Systemic Lupus Erythematosus: More Than a Positive Antinuclear Antibody
Weiss, J. E. (2012) · Pediatrics in Review · doi:10.1542/pir.33-2-62 · Cited by 55 · see citing works
Thrombosis and the Antiphospholipid Syndrome
Ortel, T. L. (2005) · Hematology · doi:10.1182/asheducation-2005.1.462 · Cited by 53 · see citing works
Lupus in Baltimore: evidence-based ‘clinical pearls’ from the Hopkins Lupus Cohort
Petri, M. (2005) · Lupus · doi:10.1191/0961203305lu2230xx · Cited by 52 · see citing works
Connective Tissue Disease–Associated Lung Disease
Olson, A. L., Brown, K. K., & Fischer, A. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.09.002 · Cited by 52 · see citing works
Shrivastava, A., Dwivedi, S., Aggarwal, A., & Misra, R. (2001) · Lupus · doi:10.1191/096120301671577528 · Cited by 51 · see citing works
Matsuura, E., & Lopez, L. R. (2004) · Journal of Immunology Research · doi:10.1080/10446670410001722186 · Cited by 50 · see citing works
“Antiphospholipid antibodies appear to increase the risk of thrombosis by at least two-fold in the context of an autoimmune disease (Wahl et al., 1997).”
BackgroundKupferminc, M. J. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053381855 · Cited by 47 · see citing works
Laboratory diagnosis and management challenges in the antiphospholipid syndrome
Bertolaccini, M. L., & Khamashta, M. A. (2006) · Lupus · doi:10.1191/0961203306lu2293rr · Cited by 47 · see citing works
Respiratory Manifestations in Systemic Lupus Erythematosus
Bartolomeo, S. D., Alunno, A., & Carubbi, F. (2021) · Pharmaceuticals · doi:10.3390/ph14030276 · Cited by 48 · see citing works
“Hydroxychloroquine may reduce thrombotic risk both in APS and non-APS SLE patients due to its pleiotropic effects but evidence in this regard is still scarce [78,85].”
BackgroundInfluentialAntiphospholipid antibodies: Paradigm in transition
Horstman, L. L., Jy, W., Bidot, C., Ahn, Y. S., Kelley, R. E., Zivadinov, R., Maghzi, A. H., Etemadifar, M., Mousavi, S. A., & Minagar, A. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-3 · Cited by 46 · see citing works
“Galli et al acknowledge this point in the concluding sentence of their abstract [244], and others have commented similarly [262,263].”
Nojima, J., Kuratsune, H., Suehisa, E., Kawasaki, T., Machii, T., Kitani, T., Iwatani, Y., & Kanakura, Y. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03642.x · Cited by 44 · see citing works
Zuily, S., Regnault, V., Guillemin, F., Kaminsky, P., Rat, A., Lecompte, T., & Wahl, D. G. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.04.012 · Cited by 44 · see citing works
“Antiphospholipid syndrome (APS) is characterized by venous or arterial thromboses [1–4], obstetric morbidity [5] associated with persistent antiphospholipid antibodies (aPL) according to the Sapporo-Sydney”
BackgroundSelf-citationAntiphospholipid (Hughes) Syndrome
Khamashta, M. A., Bertolaccini, M. L., & Hughes, G. R. V. (2004) · Autoimmunity · doi:10.1080/08916930410001708706 · Cited by 44 · see citing works
“A meta-analysis of APS and the risk of venous thrombosis in SLE found that patients who are LA positive were six times more likely to have such an event, and patients with aCL were two times more likely.([32])”
BackgroundAutoimmune-mediated atherothrombosis
Matsuura, E., & Lopez, L. (2008) · Lupus · doi:10.1177/0961203308093553 · Cited by 42 · see citing works
Epidemiology of the Antiphospholipid Syndrome
Durcan, L., & Petri, M. (2016) · Technical report · doi:10.1016/b978-0-444-63655-3.00002-8 · Cited by 43 · see citing works
Primary Prevention of Thrombosis in Subjects with Positive Antiphospholipid Antibodies
Khamashta, M. A. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.2000.0421 · Cited by 42 · see citing works
Diagnosis of antiphospholipid syndrome
Bertolaccini, M. L., Khamashta, M. A., & Hughes, G. R. V. (2005) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0017 · Cited by 40 · see citing works
“A meta-analysis of APS and the risk of venous thrombosis in SLE found that patients who were LA-positive were six times more likely than patients who were LA-negative to have such an event, and patients with aCL were twice as likely as patients without aCL to have such an event”
Bergrem, A., Jacobsen, E., Skjeldestad, F. E., Jacobsen, A. F., Skogstad, M., & Sandset, P. M. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2009.12.006 · Cited by 41 · see citing works
“In patients with systemic lupus erythematosus and other autoimmune diseases APAs are established risk factors for VT [13,14].”
BackgroundZhu, R., Cheng, C., Yang, Y., Denas, G., & Pengo, V. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.04.021 · Cited by 40 · see citing works
Pediatric Antiphospholipid Syndrome
Aguiar, C. L., Soybilgic, A., Avčin, T., & Myones, B. L. (2015) · Current Rheumatology Reports · doi:10.1007/s11926-015-0504-5 · Cited by 39 · see citing works
Alessandri, C., Bombardieri, M., Prospero, L. D., Conigliaro, P., Conti, F., Labbadia, G., Misasi, R., Sorice, M., & Valesini, G. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02727.x · Cited by 38 · see citing works
Hoppe, C. C., & Matsunaga, A. T. (2002) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(02)00092-5 · Cited by 39 · see citing works
Watanabe, T., Oku, K., Amengual, O., Hisada, R., Ohmura, K., Nakagawa, I., Shida, H., Bohgaki, T., Horita, T., Yasuda, S., et al. (2017) · Lupus · doi:10.1177/0961203317716787 · Cited by 37 · see citing works
“It has been already well recognized that aPL increases the risk for thrombosis in SLE (32-34).”
BackgroundDepascale, R., Frate, G. D., Gasparotto, M., Manfrè, V., Gatto, M., Iaccarino, L., Quartuccio, L., Vita, S. D., & Doria, A. (2021) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211040696 · Cited by 39 · see citing works
“73 Indeed, thrombotic events frequently occur in the setting of antiphospholipid antibody syndrome (APS), whose prevalence in SLE is estimated to be around 30%.”
Anti-β2-Glycoprotein I Antibodies in Patients with Acute Venous Thromboembolism
Zanon, E., Prandoni, P., Vianello, F., Saggiorato, G., Carraro, G., Bagatella, P., & Girolami, A. (1999) · Thrombosis Research · doi:10.1016/s0049-3848(99)00105-x · Cited by 38 · see citing works
Domingues, V., Magder, L. S., & Petri, M. (2016) · Lupus Science & Medicine · doi:10.1136/lupus-2015-000107 · Cited by 36 · see citing works
Thrombosis in systemic lupus erythematosus: risk and protection
Burgos, P. I., & Alarcón, G. S. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.137 · Cited by 34 · see citing works
Inherited and Acquired Thrombophilias
Rambaldi, M. P., Mecacci, F., Guaschino, S., & Paidas, M. J. (2013) · Reproductive Sciences · doi:10.1177/1933719113497282 · Cited by 35 · see citing works
Mechanisms of antiphospholipid-induced thrombosis: Effects on the protein C system
Wahl, D. G., Membré, A., Perret‐Guillaume, C., et al. (2009) · Current Rheumatology Reports · doi:10.1007/s11926-009-0011-7 · Cited by 35 · see citing works
Self-citation
- Authors
- Wahl, D., Guillemin, F., de Maistre, E., Perret, C., Lecompte, T., & Thibaut, G.
- Affiliations
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Université de Lorraine (FR)
- Laboratory of Haemostasis and Thrombosis, Nancy University Hospital, Nancy, France
- Venue
- Lupus
- Publisher
- SAGE Publications
- Published
- 1997-06
- Volume
- 6
- Issue
- 5
- Pages
- 467-473
- ISSN
- 0961-2033 (ISSN-L)
- 1477-0962
- OpenAlex
- W2080975717
- Cited by
- 284
- References
- 29
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 11 · 2023: 8 · 2022: 6 · 2021: 10 · 2020: 10 · 2019: 9 · 2018: 4 · 2017: 9 · 2016: 11 · 2015: 7 · 2014: 4 · 2013: 11 · 2012: 6
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lupus (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- venous thrombosis, antiphospholipid antibodies, systemic lupus erythematosus, lupus anticoagulant, anticardiolipin antibodies, deep vein thrombosis, pulmonary embolism, recurrent venous thrombosis
- MeSH terms
- Autoimmune Diseases, Disease Susceptibility, Epidemiologic Methods, Humans, Lupus Erythematosus, Systemic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
